You are here: Home » Current Affairs » Coronavirus » News
Business Standard

India's vaccine productivity will serve needs of all: PM to S Africa Prez

The two leaders also discussed possibilities of collaboration between India and South Africa in various international fora, to facilitate access and affordability of vaccines and medicines

Topics
Coronavirus Vaccine | Narendra Modi

Press Trust of India  |  New Delhi 

PM Narendra Modi
PM Narendra Modi

Prime Minister on Thursday told South African President Cyril Ramaphosa that India's considerable productive capacity for pharmaceuticals and vaccines would continue to serve the needs of all countries, including those in Africa.

Modi and Ramaphosa, during a telephonic conversation, discussed the continuing challenges posed by the COVID-19 pandemic, and in this context the vaccination campaigns being undertaken in their respective countries, a Prime Minister's Office (PMO) statement said.

"Spoke to President @CyrilRamaphosa about the measures India and South Africa are taking to fight the COVID-19 pandemic domestically and internationally. India's capacity to produce medicines and vaccines is supporting the efforts of many nations, including our friends in Africa," Modi said in a tweet.

The PMO also said in its statement that the prime minister reiterated to the South African president that India's considerable productive capacity for pharmaceuticals and vaccines would continue to serve the needs of all countries, including those in Africa.

The two leaders also discussed possibilities of collaboration between India and South Africa in various international fora, to facilitate access and affordability of vaccines and medicines.

Modi and Ramphosa agreed that officials of both countries would remain in touch over the coming days to exchange experiences and explore potential for collaborative efforts against the pandemic, according to the PMO.

Earlier this week, made-in-India vaccines reached South Africa in an aircraft and President Ramaphosa received the consignment of doses.

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

Dear Reader,


Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

First Published: Thu, February 04 2021. 22:41 IST
RECOMMENDED FOR YOU